{"extraction_ratio": 0.89, "to_compare": [{"generated": ["progressive mobilization", "complete normalization"], "gold": []}, {"generated": ["fourth course"], "gold": []}, {"generated": ["May 2009"], "gold": []}, {"generated": ["16"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["increased number and types of chemotherapeutic drugs", "prolonged life expectancy"], "gold": []}, {"generated": ["patient"], "gold": []}, {"generated": ["health risks", "complexity"], "gold": []}, {"generated": ["chronic back pain"], "gold": []}, {"generated": ["movement control", "low dopamine concentrations"], "gold": []}, {"generated": ["pharmacodynamic", "pharmacogenomic", "pharmacokinetic"], "gold": []}, {"generated": ["chronic neck, back, and shoulder pain", "past medical history"], "gold": []}, {"generated": ["early in the morning"], "gold": []}, {"generated": ["additional medication"], "gold": []}, {"generated": ["numerous ages found in text"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["patient\u2019s PGx results (Table 1)", "genotype for COMT Met/Met"], "gold": []}, {"generated": ["one out of five"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["past two decades"], "gold": []}, {"generated": ["2009-2010"], "gold": []}, {"generated": ["29%", "83%", "South Korean population"], "gold": []}, {"generated": ["very narrow therapeutic indices"], "gold": []}, {"generated": ["an increasing number of studies"], "gold": []}, {"generated": ["clinic", "studies", "important"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rs1142345"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["last decade"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["about 70%"], "gold": []}, {"generated": ["CYP2C9", "potential interaction", "CYP1A2", "CYP2C19"], "gold": []}, {"generated": ["K A", "non-targeted approach", "metabolites", "time course"], "gold": []}, {"generated": ["weight of original starting material", "bioavailable concentration", "bioavailability", "weight extracted powdered material", "plasma concentration", "intestinal absorption"], "gold": []}, {"generated": ["tremendous surge", "public interest"], "gold": []}, {"generated": ["chronically"], "gold": []}, {"generated": ["indigenous mode of extraction"], "gold": []}, {"generated": ["44"], "gold": []}, {"generated": ["binary pump", "serial dilutions", "Waters micromass", "column oven", "vacuum degasser", "autosampler", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "UPLC system", "mixture of regeneration system", "Acquity BEH C18 column"], "gold": []}, {"generated": ["almost all"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["clinical pharmacokinetic profile", "vivo"], "gold": []}, {"generated": ["increasing"], "gold": []}, {"generated": ["31%"], "gold": []}, {"generated": ["96 h after dose", "1, 20, 6, 14%", "1985"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["day before", "2 days after"], "gold": []}, {"generated": ["2003"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["1 : 40", "1 : 80"], "gold": []}, {"generated": ["chronic hepatitis", "periportal hepatocyte apoptosis", "moderate plasma cell rich interface hepatitis", "mild cholangiolar proliferation"], "gold": []}, {"generated": ["clinicopathological features", "Case 1", "Tables 1, 2, and 3"], "gold": []}, {"generated": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema", "initially asymptomatic"], "gold": []}, {"generated": ["vasomotor symptoms of menopause"], "gold": []}, {"generated": ["discontinuation of the herbal supplement"], "gold": []}, {"generated": ["immunogen", "metabolite", "autoimmune response", "hapten", "drug", "host cellular protein", "immune mechanism"], "gold": []}, {"generated": ["Adults"], "gold": []}, {"generated": ["differences", "similarities", "black cohosh hepatotoxicity", "case studies", "published cases"], "gold": []}, {"generated": ["third-generation fluoroquinolone antibiotic family"], "gold": []}, {"generated": ["urinary system infection"], "gold": []}, {"generated": ["in vivo distribution studies", "pharmacokinetic features"], "gold": []}, {"generated": ["rat tissue homogenate"], "gold": []}, {"generated": ["42 mg kg"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u00b115%", "acceptable limit"], "gold": []}, {"generated": ["distribution rate in the tissue", "entrance of LVFX"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pharmacodynamic interactions", "pharmacokinetic interactions"], "gold": []}, {"generated": ["2017"], "gold": []}, {"generated": ["people with diabetes"], "gold": []}, {"generated": ["anti-inflammatory", "anti-osteoporosis", "antioxidant", "anticancer"], "gold": []}, {"generated": ["Penicillin-streptomycin", "HEPES", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Trypsin EDTA", "Hanks balanced salt solution (HBSS)"], "gold": []}, {"generated": ["No ages found in text"], "gold": []}, {"generated": ["2011"], "gold": []}, {"generated": ["2006"], "gold": []}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": []}, {"generated": ["hypocholesterolemic drugs", "hypoglycemic drugs"], "gold": []}, {"generated": ["global increase in the prevalence of diabetes and obesity"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP2C8", "CYP3A4", "CYP2C9"], "gold": []}, {"generated": ["methanol", "acetonitrile", "DMSO"], "gold": []}, {"generated": ["30 min"], "gold": []}, {"generated": ["15%\u201320%"], "gold": []}, {"generated": ["10 mg/mL"], "gold": []}, {"generated": ["positive CYP2C9 inhibitor", "positive CYP3A4 inhibitor", "positive CYP2C8 inhibitor"], "gold": []}, {"generated": ["CYP3A4", "drugs metabolized by CYP2C8", "in vitro"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["well tolerated", "all participants"], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["eight"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Subsequently"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["docetaxel AUC0\u2013\u221e"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["midazolam studies"], "gold": []}, {"generated": ["leaves", "roots", "different parts of E. purpurea plants"], "gold": []}, {"generated": ["E. purpurea extracts", "CYP3A4 induction potential", "alkylamides", "gene reporter assay", "LS180 cells"], "gold": []}, {"generated": ["pharmacokinetics of docetaxel"], "gold": []}, {"generated": ["cancer patients"], "gold": []}, {"generated": ["advanced cancer"], "gold": []}, {"generated": ["product dependent"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["10 \u00b5L ethyl gallate", "100 \u00b5L plasma"], "gold": []}, {"generated": ["291.20", "151.00", "139.00", "307.20", "443.10", "127.03", "199.00", "123.00"], "gold": []}, {"generated": ["0.1", "EC", "EGC", "500 ng/mL", "EGCG", "50 ng/mL", "ECG"], "gold": []}, {"generated": ["200 \u00b5L"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Sixteen"], "gold": []}, {"generated": ["no specific age mentioned", "mild", "adults", "adolescents", "children"], "gold": []}, {"generated": ["Day 1", "Day 15"], "gold": []}, {"generated": ["Day 1", "digoxin alone treatment", "AUC"], "gold": []}, {"generated": ["systemic exposure", "reduced", "study"], "gold": []}, {"generated": ["start of the study", "ratios", "mean \u00b1 SD"], "gold": []}, {"generated": ["control group", "repeated administration group"], "gold": []}, {"generated": ["RGE", "rats", "ginsenosides", "plasma concentrations", "1 or 2 weeks"], "gold": []}, {"generated": ["rats"], "gold": []}, {"generated": ["rat plasma"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rheumatoid arthritis"], "gold": []}, {"generated": ["rheumatoid arthritis"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["Seoul, Korea"], "gold": []}, {"generated": ["liver samples", "100 mg"], "gold": []}, {"generated": ["2 h"], "gold": []}, {"generated": ["Red ginseng extract"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["RGE"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["2014"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["3.5 \u03bcm"], "gold": []}, {"generated": ["3500", "-40", "10"], "gold": []}, {"generated": ["Rat liver microsomes"], "gold": []}, {"generated": ["half-life"], "gold": []}, {"generated": ["highest recovery"], "gold": []}, {"generated": ["six different rats"], "gold": []}, {"generated": ["ng/mL", "1", "500"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["large individual differences"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["reports", "studies", "combinations"], "gold": []}, {"generated": ["neonates", "patients with renal dysfunction"], "gold": []}, {"generated": ["our analysis of the literature"], "gold": []}, {"generated": ["control rats", "experimental rats"], "gold": []}, {"generated": ["Experiments in mice"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["rats", "digoxin-induced arrhythmias"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["limited research"], "gold": []}, {"generated": ["complex"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["potential for herb-drug interactions"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["systemic levels", "two or more drugs"], "gold": []}, {"generated": ["none"], "gold": []}, {"generated": ["proper drug disposition"], "gold": []}, {"generated": ["C. asiatica"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0.1% (v/v)"], "gold": []}, {"generated": ["ambient temperature"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["means \u00b1 S.D."], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Prism 8.0.2"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": []}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["data not shown"], "gold": []}, {"generated": ["2011", "2017", "2002", "1996", "2006", "2012", "2003", "3"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["triplicate"], "gold": []}, {"generated": ["human P450 forms", "human liver microsomes", "CYP2C19", "CYP2D6", "CYP2C9", "CYP3A4"], "gold": []}, {"generated": ["plasma concentrations", "clinical studies", "CAW-R61J"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["phase II"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["chronic kidney disease"], "gold": []}, {"generated": ["Each sample"], "gold": []}, {"generated": ["high concentrations", "low concentrations", "medium concentrations"], "gold": []}, {"generated": ["berberine (IS)", "1 ng/mL", "150 \u03bcL"], "gold": []}, {"generated": ["6 \u00b0C", "24 h"], "gold": []}, {"generated": ["3 mg/kg", "5 mg/kg", "10% DMSO"], "gold": []}, {"generated": ["jejunal segments"], "gold": []}, {"generated": ["1 ng/mL", "50 \u03bcL", "150 \u03bcL"], "gold": []}, {"generated": ["product ion scan results", "authentic standards", "previously published reports"], "gold": []}, {"generated": ["1 h after", "rat plasma samples"], "gold": []}, {"generated": ["115", "85"], "gold": []}, {"generated": ["hypertension"], "gold": []}, {"generated": ["mass fragmentation patterns", "ages", "product ion mass spectra", "adults", "reported"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CV", "mean", "experiments"], "gold": []}, {"generated": ["chronic"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["developing countries"], "gold": []}, {"generated": ["most diseases"], "gold": []}, {"generated": ["26"], "gold": []}, {"generated": ["bioavailable concentration", "GI tract", "plasma concentrations", "test compound", "intestinal absorption", "soluble extract"], "gold": []}, {"generated": ["mg\u00b7kg"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["concentration-dependent inhibition"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["72 h", "24 h"], "gold": []}, {"generated": ["Ambroise Wonkam", "Dee Blackhurst", "Michelle Skelton", "Kevin Dzobo", "Denis Chopera"], "gold": []}, {"generated": ["final manuscript"], "gold": []}, {"generated": ["five major ingredients"], "gold": []}, {"generated": ["7 \u00b1 1-day washout period", "three treatments"], "gold": []}, {"generated": ["our study"], "gold": []}, {"generated": ["1000 mg", "8 tablets", "1000 mg \u00d7 4 times"], "gold": []}, {"generated": ["1000 mg \u00d7 4 times daily", "1000 mg once daily"], "gold": []}, {"generated": ["1000 mg", "7680 mg"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pharmacokinetic (PK) parameters"], "gold": []}, {"generated": ["elderly subjects"], "gold": []}, {"generated": ["greater than 65 years of age"], "gold": ["greater than 65 years of age"]}, {"generated": ["elderly"], "gold": []}, {"generated": ["five days"], "gold": []}, {"generated": ["ultraviolet absorption spectra", "retention times"], "gold": []}, {"generated": ["45"], "gold": []}, {"generated": ["presupplementation", "postsupplementation"], "gold": []}, {"generated": ["17"], "gold": []}, {"generated": ["young individuals"], "gold": []}, {"generated": ["54"], "gold": []}, {"generated": ["42"], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["various ages found in text"], "gold": []}, {"generated": ["18"], "gold": []}, {"generated": ["little effect", "specific CYP isoforms"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["conventional medications"], "gold": []}, {"generated": ["plasma quinine", "HPLC method", "3-hydroxyquinine"], "gold": []}, {"generated": ["10", "8", "11", "7", "6", "9"], "gold": []}, {"generated": ["adverse side effects from taking G. kola seeds", "breastfeeding", "pregnancy", "histories of hypersensitivity to quinine or similar agents"], "gold": []}, {"generated": ["certified healthy", "written informed consent"], "gold": []}, {"generated": ["600 mg quinine sulphate tablets", "overnight fast"], "gold": []}, {"generated": ["1, 2, 3, 4, 6, 8, 12, 24, 36, 48 h"], "gold": []}, {"generated": ["0.5\u00b5g/ml", "0.37\u00b5g/ml"], "gold": []}, {"generated": ["0\u2013\u221e"], "gold": []}, {"generated": ["very light dizziness"], "gold": []}, {"generated": ["38"], "gold": []}, {"generated": ["T1/2", "CL/F"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["77"], "gold": []}, {"generated": ["worldwide", "KwaZulu-Natal", "adults"], "gold": []}, {"generated": ["1200 mg"], "gold": []}, {"generated": ["QRS duration", "corrected QT interval (QTc)", "PR interval", "both arms", "serial electrocardiograms"], "gold": []}, {"generated": ["ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["percent", "data", "occurrence", "prevalence"], "gold": []}, {"generated": ["chronic kidney disease (CKD)", "increasing incidence"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["patients' age"], "gold": []}, {"generated": ["20\u201360 years"], "gold": ["20\u201360 years"]}, {"generated": ["13.23%"], "gold": []}, {"generated": ["50\u201370 years"], "gold": ["50\u201370 years"]}, {"generated": ["middle-aged (50\u201364)"], "gold": ["50\u201364"]}, {"generated": [], "gold": []}, {"generated": ["27"], "gold": []}, {"generated": ["90%"], "gold": []}, {"generated": ["2 months", "18 F"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0.5 mL", "6 min"], "gold": []}, {"generated": ["each blood sampling time"], "gold": []}, {"generated": ["clotting time", "known factor activity", "standard human plasma"], "gold": []}, {"generated": ["half-life", "apparent clearance (CL/F)", "ln 2/kel", "AUC0-\u221e", "dose", "CL/kel", "apparent volume of distribution (V/F)"], "gold": []}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "INR data"], "gold": []}, {"generated": ["data not shown"], "gold": []}, {"generated": ["1.4 (1.1\u20131.6)", "0.010 (0.007\u20130.014)", "1.12 (0.39\u20131.84)", "1.3 (1.1\u20131.6)", "0.94 (0.67\u20131.47)", "65.5 (55.3\u201375.6)", "1.9 (1.1\u20132.7)", "1.9 (1.5\u20132.2)", "1.04 (0.94\u20131.67)", "NA", "63.0 (57.3\u201368.8)", "60.3 (54.5\u201366.1)", "1.06 (0.95\u20131.19)", "0.010 (0.007\u20130.013)", "1.06 (0.83\u20131.19)", "1.8 (1.7\u20131.9)", "1.7 (1.5\u20132.0)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2007"], "gold": []}, {"generated": ["7 patients"], "gold": []}, {"generated": ["2007"], "gold": []}, {"generated": ["patients", "adults", "common"], "gold": []}, {"generated": ["popular publications", "directed to cancer patients", "information websites", "recent"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["600 mg"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["conclusions", "data", "studies", "results"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["36"], "gold": []}, {"generated": ["14 subsequent days"], "gold": []}, {"generated": ["hydroxychlorzoxazone/chlorzoxazone serum ratio", "debrisoquine urinary recovery ratio", "paraxanthine/caffeine serum ratio", "1-hydroxymidazolam/midazolam serum ratio"], "gold": []}, {"generated": ["12 weeks", "15 days"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["two case reports"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["essential", "clinical risks"], "gold": []}, {"generated": ["in vivo", "in vitro"], "gold": []}, {"generated": ["valid clinical observations", "relevant risk"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["P-gp", "CYP-isoenzymes", "UGT"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["7 days"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["normalization of the LVEF", "rapid improvement", "regression of the radiological abnormalities"], "gold": []}, {"generated": ["drug-induced cardiopulmonary toxicity"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["probably associated with venlafaxine"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["metaboliza\u00e7\u00e3o lenta", "circunstancial"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["maioria"], "gold": []}, {"generated": ["35 anos de idade"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["menopausal symptoms"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["degree of adverse reaction", "date of disappearance", "result of adverse reaction", "date of onset"], "gold": []}, {"generated": ["ages", "demographic information", "statistically significant difference"], "gold": []}, {"generated": ["p-value", "Fisher's exact test"], "gold": []}, {"generated": ["fully recovered"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["large-scale", "long period"], "gold": []}, {"generated": ["UGT2B7", "UGT1A1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Dixon", "intersection", "vertical axis", "Lineweaver-Burk plots", "second quadrant"], "gold": []}, {"generated": ["0.49 \u03bcM"], "gold": []}, {"generated": ["13-fold", "120-fold"], "gold": []}, {"generated": ["many drugs"], "gold": []}, {"generated": ["previous"], "gold": []}, {"generated": ["AGE: Not specified"], "gold": []}, {"generated": ["chronic liver disease"], "gold": []}, {"generated": ["0.5\u20132.0 g/kg"], "gold": []}, {"generated": ["rats", "human"], "gold": []}, {"generated": ["RGE", "Rc", "high dose", "valsartan", "repeated administration"], "gold": []}, {"generated": ["7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%", "34.1 \u03bcM"], "gold": []}, {"generated": ["\u221280 \u00b0C", "10 min", "50 \u03bcL", "16,000\u00d7 g"], "gold": []}, {"generated": ["2", "0.33", "8", "0.67", "4", "48", "1.5", "24", "0.17"], "gold": []}, {"generated": ["1-week"], "gold": []}, {"generated": ["0 to 48 h"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u00b11 day"], "gold": []}, {"generated": ["24 subjects"], "gold": []}, {"generated": ["malondialdehyde (MDA)"], "gold": []}, {"generated": ["disease of antioxidant deficiency"], "gold": []}, {"generated": ["markedly"], "gold": []}, {"generated": ["OS"], "gold": []}, {"generated": ["C. sinensis"], "gold": []}, {"generated": ["4 \u00b0C", "4 h", "200 \u00b5L", "1 mL", "120 g"], "gold": []}, {"generated": ["1,1\u2032,3,3\u2032-tetramethoxypropane", "0.54\u20131,32 pg/mL"], "gold": []}, {"generated": ["described"], "gold": []}, {"generated": ["75", "25"], "gold": []}, {"generated": ["group 2", "group 1", "group 3"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["FBS level", "pancreatic \u03b2 cells"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["insulin tolerance", "significant reduction", "glucose levels"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["longer follow-up", "proliferative and secretory phases"], "gold": []}, {"generated": ["patients"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["20", "2006"], "gold": []}, {"generated": ["V05895B"], "gold": []}, {"generated": ["days 0, 14, and 28"], "gold": []}, {"generated": ["natural log transformed", "analysis of variance model", "confidence intervals", "treatment"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["<50 copies/ml"], "gold": []}, {"generated": ["Darunavir"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["antiretroviral agents", "botanicals", "clinical pharmacokinetic interactions"], "gold": []}, {"generated": ["darunavir pharmacokinetics", "variability"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no relevant effect on the in vivo activity of the major CYP enzymes in humans"], "gold": []}, {"generated": ["variety of disorders"], "gold": []}, {"generated": ["8 days"], "gold": []}, {"generated": ["5-OH-OME", "DEX", "DOR", "internal standard", "precipitation", "OME", "MID assays"], "gold": []}, {"generated": ["standard bioequivalence approach"], "gold": []}, {"generated": ["120"], "gold": []}, {"generated": ["240-mg EGb 761\u00ae daily dose", "1 week"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["8-day period"], "gold": []}, {"generated": ["pharmacokinetic (PK)", "pharmacodynamic (PD)", "randomized controlled trials"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["standard eligibility inclusion criteria"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["28", "26", "29", "24", "21"], "gold": []}, {"generated": ["unclear risk of bias", "minimum age", "high risk of bias", "minus (-) marked circle"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["different ages found in text"], "gold": []}, {"generated": ["potential herb-warfarin interaction"], "gold": []}, {"generated": ["multiple reasons"], "gold": []}, {"generated": ["drugs metabolized by CYP2C9", "in vivo study"], "gold": []}, {"generated": ["48", "dose-dependent manner", "hepatic damage", "in vivo study"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no history of warfarin use", "detected in her blood serum analysis"], "gold": []}, {"generated": ["greater than seven", "more than 70 seconds", "more than 37 seconds"], "gold": []}, {"generated": ["unknown DIC", "unknown pathologic inhibitors", "unknown vitamin K malabsorption", "unknown origin", "unknown coagulopathy"], "gold": []}, {"generated": ["study protocol", "subject enrollment"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["human pharmacokinetic data", "well\u2010characterized composition", "in vitro inhibitory potency"], "gold": []}, {"generated": ["raloxifene", "multiple dosing", "alternate study designs", "silibinin predosing"], "gold": []}, {"generated": ["conjugative metabolism", "oxidative metabolism"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["95%"], "gold": []}, {"generated": ["4-hour", "12-hour", "3-hour", "10-hour", "6-hour", "8-hour"], "gold": []}, {"generated": ["curcumin"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["comprehensive systematic review", "existing literature"], "gold": []}, {"generated": ["2012"], "gold": []}, {"generated": ["2012"], "gold": []}, {"generated": ["rabbits", "human"], "gold": []}, {"generated": ["rats", "two children"], "gold": []}, {"generated": ["long-term basis"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["reduced the plasma level of CBZ"], "gold": []}, {"generated": ["Caution"], "gold": []}, {"generated": ["patients with major depression or bipolar disorder"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["proactive monitoring"], "gold": []}, {"generated": ["significant relationship", "variables", "p < 0.05"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["highest number of patients with type-2 diabetes", "that age group"], "gold": []}, {"generated": ["patients", "hypoglycaemic agents", "Tabular summary", "pharmacological management"], "gold": []}, {"generated": ["12 identified plants"], "gold": []}, {"generated": ["patients with diabetes"], "gold": []}, {"generated": [], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["thousands of years"], "gold": []}, {"generated": ["hepatocellular carcinoma"], "gold": []}, {"generated": ["15 min"], "gold": []}, {"generated": ["22 compounds"], "gold": []}, {"generated": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "gold": []}, {"generated": ["human"], "gold": []}, {"generated": ["Ultimate 3000 UPLC system", "LTQ-Orbitrap Elite mass spectrometer", "UPLC-MS/MS analysis", "notoginsenoside R"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2 \u00d7 10 Total RNA"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["whole experiments"], "gold": []}, {"generated": ["p < 0.01", "p < 0.001"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["drug transporters", "cytochrome P450 enzymes", "CYPs"], "gold": []}, {"generated": ["L-MDR1 cells", "human P-glycoprotein (P-gp)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["minor effect"], "gold": []}, {"generated": ["in vitro"], "gold": []}, {"generated": ["concomitantly used drugs"], "gold": []}, {"generated": ["MDCKII-BCRP cells", "parental cell line MDCKII"], "gold": []}, {"generated": ["positively controls", "published previously"], "gold": []}, {"generated": ["1%", "Banderol", "Samento"], "gold": []}, {"generated": ["RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit", "miniprep Kit"], "gold": []}, {"generated": ["previous"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Reporter gene assays"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["four days"], "gold": []}, {"generated": ["LS180 cells"], "gold": []}, {"generated": ["t = 0"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["original formulation"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2 weeks"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["throughout the study"], "gold": []}, {"generated": ["5500 V", "500\u00b0C"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0,\u221e"], "gold": []}, {"generated": ["90% confidence intervals"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["different types of statins"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["69.90%", "65.38%"], "gold": []}, {"generated": ["Figure 5A,B"], "gold": []}, {"generated": ["66.77%", "41.06%"], "gold": []}, {"generated": ["pharmacokinetic disposition"], "gold": []}, {"generated": ["DAS", "pharmacokinetic interaction", "determine"], "gold": []}, {"generated": ["DAS 25 mg/kg"], "gold": []}, {"generated": ["one week", "12 h", "12-h"], "gold": []}, {"generated": ["Group I", "25 mg/kg", "7 days", "Group II"], "gold": []}, {"generated": ["40 mg/kg", "7 days", "2 hours", "7th day"], "gold": []}, {"generated": ["positive direction", "electrospray ionization"], "gold": []}, {"generated": ["humans", "in vivo studies"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["KSU-SE-21-58"], "gold": []}, {"generated": ["mean age", "sample age", "age group", "standard deviation", "subject age", "patient age", "age range", "average age"], "gold": []}, {"generated": ["rats", "APG pretreatment", "DAS administration"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["population", "herb-mediated changes"], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["adult women"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["27", "26"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u221280 \u00b0C"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["height, weight, or BMI at baseline"], "gold": []}, {"generated": ["baseline", "12 weeks"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["about 20 years ago"], "gold": []}, {"generated": ["pregnane-X-receptor"], "gold": []}, {"generated": ["2017", "2004", "2009", "2006", "2012", "2019"], "gold": []}, {"generated": ["potentially relevant targets for depression"], "gold": []}, {"generated": ["time of immobility"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["recently", "2019", "2018"], "gold": []}, {"generated": ["low\u2010hyperforin", "seven test drugs"], "gold": []}, {"generated": ["high quality clinical data", "cancer therapies"], "gold": []}, {"generated": ["Lingzhi", "Yunzhi"], "gold": []}, {"generated": ["significant dosage differences"], "gold": []}, {"generated": ["Figure 1"], "gold": []}, {"generated": ["111", "145", "67", "105", "144", "63", "99", "101", "83", "20", "103", "84", "98", "141"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["reactive oxygen species production", "tumor cell angiogenesis"], "gold": []}, {"generated": ["tumor metabolism", "gut dysbiosis induced by paclitaxel", "recent study"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["Multiple ages not specified"], "gold": []}, {"generated": ["adverse effects", "clinical settings", "chemotherapeutic drugs"], "gold": []}, {"generated": ["Table S4"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["described ages found in text"], "gold": []}, {"generated": ["conventional cancer therapy", "frequently"], "gold": []}, {"generated": ["70\u201380%"], "gold": []}, {"generated": ["breast cancer patients", "other types of cancer"], "gold": []}, {"generated": ["5\u2009mg", "306\u2009ng/mL"], "gold": []}, {"generated": ["\u03b2-estradiol", "dextrorphan-d", "human liver microsomes", "4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs"], "gold": []}, {"generated": ["concentration-dependent inhibition of proliferation"], "gold": []}, {"generated": ["patients", "enzyme phenotypes", "metabolizers"], "gold": []}, {"generated": ["long-term outcomes", "studies"], "gold": []}, {"generated": ["50 donors"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["0.1", "10", "2", "1", "100", "5"], "gold": []}, {"generated": ["Springer Nature"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["30 min", "30 seconds", "520 ppm", "180 \u00b5L", "5% ammonia", "2-4-dibromoacetophenone"], "gold": []}, {"generated": ["morning", "4.5 mg/200 g BW", "single", "two weeks"], "gold": []}, {"generated": ["anaesthetized"], "gold": []}, {"generated": ["1.0 mL"], "gold": []}, {"generated": ["within-run accuracy", "captopril analysis", "precision"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["plasma sulfhydryl groups", "captopril", "2-4-dibromoacetophenone"], "gold": []}, {"generated": ["basic pH"], "gold": []}, {"generated": ["17"], "gold": []}, {"generated": ["expression of the PEPT1 transporter", "GSH level", "coadministration", "H. sabdariffa extract", "Two weeks"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["laboratory rodent"], "gold": []}, {"generated": ["Agilent 1290 series"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["might occur"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [""], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["anti-diabetic"], "gold": []}, {"generated": ["probably", "during the course of his treatment"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["seven days"], "gold": []}, {"generated": ["previous filtrate", "filtered"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["elderly", "adolescents"], "gold": []}, {"generated": ["0.642min", "0.482min"], "gold": []}, {"generated": ["liver damage", "oxidative stress", "inflammatory response", "diabetes"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["diabetic control group", "significantly different from normal group"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["9"], "gold": []}, {"generated": ["diabetic control group", "significantly different from normal group"], "gold": []}, {"generated": ["significant alterations"], "gold": []}, {"generated": ["rats"], "gold": []}, {"generated": ["plasma sample preparation", "tissue homogenates"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["4\u20135 h", "1\u20132 h", "5\u20136 h", "2\u20133 h", "3\u20134 h", "0\u20131 h", "6\u20137 h"], "gold": []}, {"generated": ["18\u201328 h", "6\u201318 h", "0\u20136 h"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["indomethacin-induced gastric injury"], "gold": []}, {"generated": ["plasma concentration-time curves", "S-AOE", "indomethacin", "M-AOE", "model group"], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["2.5", "1.7", "1.875"], "gold": []}, {"generated": ["occasionally", "moderate intake", "375 ml"], "gold": []}, {"generated": ["no ages found"], "gold": []}, {"generated": ["daily diet"], "gold": []}, {"generated": ["10%"], "gold": []}, {"generated": ["three patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["dose dependent manner"], "gold": []}, {"generated": ["high relative quantities"], "gold": []}, {"generated": ["44, 45"], "gold": []}, {"generated": ["7.2"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["15 day"], "gold": []}, {"generated": ["most studies"], "gold": []}, {"generated": ["active site", "ACE inhibition", "cyclooxygenase inhibitory activity", "several potential mechanisms", "endothelium-derived relaxant pathways", "hypotensive activity", "anthocyanins", "PI3-K/Akt pathway", "reduction of myocardial mass", "calcium influx", "adipocyte differentiation", "new vessel formation", "ERK pathway", "blood viscosity"], "gold": []}, {"generated": ["extremely high doses", "lower doses"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["early version", "customers"], "gold": []}, {"generated": ["clinical importance"], "gold": []}, {"generated": ["clinically-relevant dose", "three-fold increase"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["21"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["senior citizens", "elderly", "adolescents"], "gold": []}, {"generated": ["human liver microsomes (HLM)", "potential mechanism\u2010based inhibitors", "in vitro"], "gold": []}, {"generated": ["Selleckchem, Houston, TX, USA", "cooling block"], "gold": []}, {"generated": ["competitive", "noncompetitive", "mixed-inhibition"], "gold": []}, {"generated": ["clinical setting"], "gold": []}, {"generated": ["different tissues"], "gold": []}, {"generated": ["tissue-to-plasma partition coefficients"], "gold": []}, {"generated": ["three lignans"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["72"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["different cancer cell lines"], "gold": []}, {"generated": ["haemorrhage"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Western blot", "Real Time-Polymerase Chain Reaction"], "gold": []}, {"generated": ["pharmacodynamic analysis"], "gold": []}, {"generated": ["2005"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["13 min", "10 min", "30 min", "5 min", "90 min", "12 min"], "gold": []}, {"generated": ["420%"], "gold": []}, {"generated": ["vehicle control group", "mRNA expression level of CYP2C6", "doses of Danshen"], "gold": []}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": []}, {"generated": ["24", "32"], "gold": []}, {"generated": ["rats", "previous study"], "gold": []}, {"generated": ["taken together with the results of the current study"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rats", "human", "several different species"], "gold": []}, {"generated": ["warfarin dose"], "gold": []}, {"generated": ["57"], "gold": []}, {"generated": ["warfarin hydroxylation"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["in vivo", "in vitro"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["early stage breast cancer"], "gold": []}, {"generated": ["publication"], "gold": []}, {"generated": ["88%", "mean recovery"], "gold": []}, {"generated": ["extracted ion chromatograms", "interference with drug quantitation"], "gold": []}, {"generated": ["113 months", "37 months", "4 months"], "gold": []}, {"generated": ["Competing interests"], "gold": []}, {"generated": ["patients with terminal diseases", "chronically ill patients"], "gold": []}, {"generated": ["antimicrobials", "asthma", "cancer", "hypertension", "peptic ulcer", "minor ailments", "chronic diseases", "antimalarials", "diabetes"], "gold": []}, {"generated": ["over 70%"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["freeze-dried", "concentrated", "filtered"], "gold": []}, {"generated": ["Darmstadt", "LiChrosolv GG", "Germany", "Merck"], "gold": []}, {"generated": ["2005", "2007", "2013"], "gold": []}, {"generated": ["Multiple reaction monitoring (MRM) mode", "positive ion mode"], "gold": []}, {"generated": ["Fifty percent inhibitory concentration", "concentration of aqueous extract of herb"], "gold": []}, {"generated": ["commonly used herbs"], "gold": []}, {"generated": ["eight major human CYP isoenzymes", "three of the plants", "highest dose of the extract"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["oven\u2010dried Allium sativum bulbs"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Strandell"], "gold": []}, {"generated": ["2000"], "gold": []}, {"generated": ["CYP2C19", "CYP3A4", "CYP1A2"], "gold": []}, {"generated": ["menopause"], "gold": []}, {"generated": ["cognitive declines", "sexual dysfunction", "hot flashes", "night sweats", "sleep disturbances", "transition to menopause", "mood disorders", "weight gain", "problematic symptoms"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages mentioned"], "gold": []}, {"generated": ["30 days"], "gold": []}, {"generated": ["851", "14 days"], "gold": []}, {"generated": ["sequentially numbered"], "gold": []}, {"generated": ["Figure 4", "mean (SD)", "plasma concentrations", "simvastatin hydroxy acid", "simvastatin", "internal standard", "lovastatin"], "gold": []}, {"generated": ["mean (SD)"], "gold": []}, {"generated": ["P < 0.05"], "gold": []}, {"generated": ["40 mg"], "gold": []}, {"generated": ["worldwide popularity"], "gold": []}, {"generated": ["65-year-old"], "gold": ["65-year-old"]}, {"generated": ["illnesses"], "gold": []}, {"generated": ["possible interactions", "lifestyle", "measures"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["All subjects"], "gold": []}, {"generated": ["2 weeks", "n= 12"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["previous studies"], "gold": []}, {"generated": ["health care professionals", "high levels of herb-drug use", "earlier surveys"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["In vitro", "first stage", "herb-drug interactions", "potential"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["type 1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "High resolution LC-MS", "Mass Lynx V4.1 software", "Waters Micromass Ltd.", "HPLC conditions"], "gold": []}, {"generated": ["15"], "gold": []}, {"generated": ["35"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["significantly (p \u2264 0.05)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["ages found in text"], "gold": []}, {"generated": ["Five days"], "gold": []}, {"generated": ["well-studied treatment"], "gold": []}, {"generated": ["extract", "refractory"], "gold": []}, {"generated": ["selected single herbs", "Wen Bing formulas"], "gold": []}, {"generated": ["1902"], "gold": []}, {"generated": ["as internal standard"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["600 \u03bcL", "8 mg/mL", "5 \u03bcL"], "gold": []}, {"generated": ["8 PM", "30 minutes", "Day 5"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["all the herb/herbal components", "significantly suppressed"], "gold": []}, {"generated": ["ten marker components", "teen"], "gold": []}, {"generated": ["anti-influenza herbs/herbal components", "in-vitro experiments"], "gold": []}, {"generated": ["decrease", "significantly increase"], "gold": []}, {"generated": ["AGE", "OS ratio", "rat urine samples", "Renal senescence", "oxidative stress", "OSA", "AGEs"], "gold": []}, {"generated": ["S8"], "gold": []}, {"generated": ["influenza viruses"], "gold": []}, {"generated": ["100 \u03bcg/mL", "500 \u03bcg/mL", "rat plasma"], "gold": []}, {"generated": ["rat plasma"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["six-dimension in-vitro screening", "62%", "after co-administration", "metabolic clearance (CL", "in-vivo pharmacokinetics in rats", "pop-PK model", "absorption rate (k", "ex-vivo pharmacodynamic evaluation", "Table 1"], "gold": []}, {"generated": ["Root of Isatis indigotica Fort., Banlangen"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pre-clinical studies"], "gold": []}, {"generated": ["breast cancer patients", "all the cancer patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["MCF7", "TAM", "T47D", "recent study"], "gold": []}, {"generated": ["T-47D", "MCF-7"], "gold": []}, {"generated": ["many European countries"], "gold": []}, {"generated": ["10 Evn-50", "2012"], "gold": []}, {"generated": ["12 traditional herbs"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2015"], "gold": []}, {"generated": ["rats", "glutathione", "sGOT", "TAM-intoxicated liver injury", "liver transaminases", "sGPT", "antioxidant enzymes", "TBARS", "significant increase"], "gold": []}, {"generated": ["2009"], "gold": []}, {"generated": ["OAT1/3", "GA", "BCRP", "PCA", "MDR1", "HDI", "in vitro"], "gold": []}, {"generated": ["2000\u20132019"], "gold": []}, {"generated": ["urinary tract infections", "prostatitis", "pyelonephritis"], "gold": []}, {"generated": ["pharmacokinetic-based HDIs", "GA", "tissue distribution-based HDIs", "PCA", "PCE"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2012", "1990", "2006", "2007"], "gold": []}, {"generated": ["11.5\u201313.5 min", "8.7\u201311 min", "0\u20138.5 min", "14\u201315 min"], "gold": []}, {"generated": ["quantification"], "gold": []}, {"generated": ["288.1", "362.2", "318.1", "332.1"], "gold": []}, {"generated": ["PK changes of GA and PCA", "Figures 3, 4", "co-administration of CIP and PCE"], "gold": []}, {"generated": ["intravenous administration", "intragastric administration"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["approximately 1%", "approximately 10%"], "gold": []}, {"generated": ["2021ZD017", "2018ZX09734-002", "2021ZD030"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["similar", "laboratory"], "gold": []}, {"generated": ["extremely", "not at all"], "gold": []}, {"generated": ["15.00", "13.3"], "gold": []}, {"generated": ["treatment (YM vs. PLC)", "Total Energy Expenditure (TEE)", "exercise time (Figure 3)"], "gold": []}, {"generated": ["low to moderate exercise intensities", "24% increase"], "gold": []}, {"generated": ["12 weeks"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["bioavailability", "active ingredients"], "gold": []}, {"generated": ["mood state", "satiety", "favorable psychomotor effects"], "gold": []}, {"generated": ["future research", "longitudinal YM effectiveness", "physically active", "lower BF% percentile"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Seoul, Korea"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["ad libitum"], "gold": []}, {"generated": ["Rats"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["various patient demographics"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP450 family", "DMEs"], "gold": []}, {"generated": ["further", "clinical", "anecdotal"], "gold": []}, {"generated": ["general well-being", "clinically significant improvement", "symptoms of cognition decline", "memory loss", "anxiety and mood disorders", "fatigue", "cardiovascular disorders"], "gold": []}, {"generated": ["subtherapeutic"], "gold": []}, {"generated": ["human studies", "midazolam"], "gold": []}, {"generated": ["itself", "chronic use"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["18"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["21"], "gold": []}, {"generated": ["herbal products"], "gold": []}, {"generated": ["different herbal species", "many marketed herbal products"], "gold": []}, {"generated": ["human small intestinal enterocytes"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["natural bioactive compounds", "drugs", "rich sources"], "gold": []}, {"generated": ["kidney transplantation"], "gold": []}, {"generated": ["age found in text"], "gold": []}, {"generated": ["April 2016"], "gold": []}, {"generated": ["74.27"], "gold": []}, {"generated": ["serious adverse effects"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["graft rejection"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [""], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["74.27"], "gold": []}, {"generated": ["possible effect"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["n = 6", "mean \u00b1 S. D."], "gold": []}, {"generated": ["groups 2 and 3", "groups 1 and 2", "statistically significant differences"], "gold": []}, {"generated": ["Zuccotti Park"], "gold": []}, {"generated": ["pretreatment period", "possible herbal drug effect"], "gold": []}, {"generated": ["evaporated", "dryness", "combined"], "gold": []}, {"generated": ["patients", "senior citizens", "available", "elderly"], "gold": []}, {"generated": ["Europe", "regulatory environment", "practical effects"], "gold": []}, {"generated": ["less knowledge"], "gold": []}, {"generated": ["years"], "gold": []}, {"generated": ["most frequently occurring species"], "gold": []}, {"generated": ["56.6%"], "gold": []}, {"generated": ["described in text"], "gold": []}, {"generated": ["two studies"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["safe daily dose"], "gold": []}, {"generated": ["short-term", "time until surgical intervention"], "gold": []}, {"generated": ["500 mg", "2\u20133 days"], "gold": []}, {"generated": ["insufficiently defined product quality"], "gold": []}, {"generated": ["emerging"], "gold": []}, {"generated": ["teenagers", "older adults"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["154"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["2018"], "gold": []}, {"generated": ["more frequently", "these groups"], "gold": []}, {"generated": ["3 weeks"], "gold": []}, {"generated": ["unusually susceptible", "individual genotype"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["human"], "gold": []}, {"generated": ["weekly", "7.5", "28%", "15"], "gold": []}, {"generated": ["individual susceptibility"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["great proportion"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["published maps", "institutional affiliations"], "gold": []}, {"generated": ["variety of ages found in text"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["pharmacodynamic", "HDI"], "gold": []}, {"generated": ["allyl thiosulfinates (mainly allicin)", "large number of sulfur compounds", "allyl thiosulfinates", "bioactive compounds"], "gold": []}, {"generated": ["two millennia"], "gold": []}, {"generated": ["individuals with diabetes"], "gold": []}, {"generated": ["experimental"], "gold": []}, {"generated": ["conventional antidiabetics"], "gold": []}, {"generated": ["98"], "gold": []}, {"generated": ["relevant chemical and pharmacological data", "more complex interactions", "complex herbal interventions"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["Springer Nature"], "gold": []}, {"generated": ["various ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["several studies"], "gold": []}, {"generated": ["USP reference standard"], "gold": []}, {"generated": ["HPLC determinations", "HPLC grade solvents", "General-purpose reagents"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["significant P value \u2a7d0.05"], "gold": []}, {"generated": ["in vitro", "concentration dependent manner"], "gold": []}, {"generated": ["25 \u03bcg/ml"], "gold": []}, {"generated": ["healthy human volunteers"], "gold": []}, {"generated": ["clinical study"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["abemaciclib-related diarrhea", "quality of life", "patients' outcomes"], "gold": []}, {"generated": [], "gold": []}]}